AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 6 analysts
Fundamentals
Fundamentals institutional score is 97 using growth durability 97.3.
Valuation
Valuation institutional score is 14 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 66 using mean target upside 4.0%; dispersion penalty 8.8; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 16 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 65.7% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.97). Confidence: 80%.
Live forward EPS implies next-12-month EPS of ₹25.09. Applying the stock's normalized valuation corridor produces a fair range of ₹1,100.20 to ₹1,428.12, with base value near ₹1,272.56 (-11.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹25.09
Forward P/E
57.6x
Base Fair Value
₹1,272.56
Fair Range
₹1,100.20 - ₹1,428.12
Upside To Base
-11.9%
Estimate Source
Live forward EPS
Growth Estimate
+20.8%
5Y Average
54.01
Current
84.03
Overvalued
56.92
Undervalued
43.85
5Y Average
29.50
Current
45.89
Overvalued
32.28
Undervalued
24.48
5Y Average
8.76
Current
13.63
Overvalued
9.59
Undervalued
7.27
Peers & Comparison
Sector: Health Care · Theme: Biotechnology
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ANTHEM BIOSCIENCES LTD ANTHEMBiotechnology | -22.6% | 28.7% | 84.0x Fair | -6% vs avg | +18.1% |
BIOCON LIMITED. BIOCONBiotechnology | +10.0% | 2.9% | 124.9x Premium | +40% vs avg | +20.1% |
ACUTAAS CHEMICALS LIMITED ACUTAASBiotechnology | +59.1% | 26.4% | 93.3x Fair | +5% vs avg | +149.2% |
ONESOURCE SPECL PHARMA L ONESOURCEBiotechnology | +37.2% | -3.1% | — | — | -16.9% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 54.5x Undervalued | -39% vs avg | +10.4% |
SAI LIFE SCIENCES LIMITED trades in line with peers (84.0x vs avg 89.2x), reflecting a fair valuation within the Biotechnology cohort. Peers include ANTHEM BIOSCIENCES LTD, BIOCON LIMITED., ACUTAAS CHEMICALS LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹549 CrDec 2025Latest net profit
₹106 CrDec 2025Latest EPS
₹4.64Dec 2025Net margin
25.2%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 373 | 428 | 264 | 382 | 429 | 567 | 483 | 527 | 549 |
| Expenses | 279 | 301 | 240 | 281 | 317 | 413 | 370 | 387 | 370 |
| Operating Profit | 65.21 | 98.55 | -3.51 | 67.99 | 80.12 | 120 | 78.68 | 104 | 138 |
| OPM % | 17.5% | 23.05% | -1.33% | 17.8% | 18.69% | 21.13% | 16.29% | 19.68% | 25.2% |
| Other Income | 10.61 | 4.19 | 8.12 | 9.95 | 9.45 | 9.82 | 10.01 | 14.93 | 8.45 |
| Interest | 21.7 | 19.42 | 19.77 | 19.45 | 21.66 | 9.16 | 10.7 | 7.7 | 8.06 |
| Depreciation | 28.3 | 28 | 28.09 | 32.78 | 31.07 | 34.1 | 34.33 | 36.21 | 40.6 |
| Profit before tax | 54.12 | 83.32 | -15.16 | 58.49 | 67.91 | 120 | 77.99 | 111 | 139 |
| Tax % | 25.76% | 26.19% | 24.93% | 25.03% | 24.81% | 25.34% | 25.16% | 25.18% | 23.67% |
| Net Profit | 40.18 | 61.5 | -11.38 | 43.85 | 51.06 | 89.94 | 58.37 | 82.95 | 106 |
| EPS in Rs | 2.22 | 3.39 | -0.63 | 2.35 | 2.74 | 4.32 | 2.80 | 3.97 | 4.64 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.